Guideline
2025 focused update of the ESC/EAS dyslipidaemia guidelines
Status Current European guideline
Presented at ESC Congress 2025 (Madrid); Mach, Koskinas, Roeters van Lennep and colleagues, European Heart Journal 2025. Revises the LDL-C pathway around earlier combination therapy and keeps lipoprotein(a) as a once-in-a-lifetime measurement and risk modifier, noting that outcomes evidence for specific Lp(a) lowering is still awaited (the first such trial, Lp(a)HORIZON, has since read out neutral in November 2026). See the two ESC 2025 videos in Video.
Page updated 10 November 2026.